Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Trident Pharmaceuticals Inc.
DescriptionOral formulation of recombinant form of the non-toxic B subunit of Escherichia coli enterotoxin
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationAsthma
Indication DetailsTreat asthma; Treat mild to moderate allergic asthma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today